Navelbine (Vinorelbine)

Vinorelbine, the active ingredient in Navelbine, is a Vinca alkaloid presented as a capsule for oral use. It treats non‑small cell lung cancer, breast cancer and other solid tumors in adult patients. GNH USA supplies Navelbine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Vinorelbine is used in chemotherapy regimens targeting solid tumours and related disease pathways. - Non‑small cell lung cancer: Improves disease control and may extend survival when used as part of standard chemotherapy regimens. - Breast cancer: Contributes to tumour reduction and progression delay in combination therapy for advanced disease. - Other solid tumours: Provides antineoplastic activity in a range of metastatic solid tumours when incorporated into multi‑agent protocols.

Vinorelbine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Neutropenia: reduced white blood cell count increasing infection risk. - Nausea and vomiting: gastrointestinal upset common during treatment. - Fatigue: persistent tiredness affecting daily activities. - Constipation: decreased bowel motility. - Alopecia: hair loss that may be temporary. - Anemia: lowered red blood cell levels causing weakness.

Serious or Rare Side Effects: - Severe neutropenia with fever: may lead to life‑threatening infection. - Pulmonary toxicity: cough, dyspnoea, or interstitial pneumonitis. - Peripheral neuropathy: tingling or numbness in extremities. - Severe allergic reactions: rash, swelling, or anaphylaxis. - Cardiac arrhythmias: irregular heart rhythm requiring monitoring. - Febrile neutropenia: high fever with low neutrophil count.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor for toxicity. - Monitor blood counts: perform regular CBC to detect neutropenia and anemia. - Assess liver function: adjust dosing in hepatic impairment. - Avoid in severe bone‑marrow suppression: contraindicated when baseline counts are critically low. - Use antiemetics prophylactically: reduce nausea and vomiting incidence. - Pregnancy safety: unknown; avoid use in pregnant women unless benefits outweigh risks. - Store at ambient temperature: keep in original container, protect from moisture and light.

Vinorelbine can interact with other medicines that affect its metabolism or bone‑marrow toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase vinorelbine exposure and toxicity. - Concurrent myelosuppressive agents: can cause severe bone‑marrow suppression.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce vinorelbine effectiveness. - QT‑prolonging drugs: increase risk of cardiac arrhythmias. - Anticoagulants: may heighten bleeding tendency. - Live vaccines: altered immune response; consider timing of administration.